India Pharma Outlook Team | Tuesday, 28 April 2026
Eli Lilly and Company is making a fresh move in blood cancer treatment with its plan to acquire Ajax Therapeutics for up to USD 2.3 billion.
The deal shows how Eli Lilly is doubling down on blood cancer therapies as it looks to build a stronger pipeline for future treatments.
The acquisition centers on Ajax’s lead drug candidate, AJ1-11095, an oral therapy now in early-stage trials.
It is being developed to treat myelofibrosis, a rare blood cancer with limited long-term treatment options. The drug targets the JAK2 protein, which plays a key role in the disease, and is designed to deliver deeper and longer-lasting responses than current therapies.
Also Read: AI-Augmented Clinical Trials & Drug Development Evolution in India
Eli Lilly targets blood cancer with Ajax Therapeutics deal as part of a broader push to invest in early but promising science. Existing treatments for myelofibrosis often help manage symptoms but can lose impact over time. Ajax’s approach aims to overcome that challenge, especially for patients who no longer respond to available drugs.
The total value of the deal could reach $2.3 billion, including milestone payments tied to development and regulatory progress. This structure allows Lilly to spread risk while securing access to a potential breakthrough therapy.
The move also reflects a larger trend across the pharma industry, where major companies are actively acquiring smaller biotech firms to stay ahead in high-growth areas like oncology. With strong revenues from its current portfolio, Eli Lilly is using its position to invest in future innovation and strengthen its presence in cancer care.
.jpg)
.jpg)
